



**A**

No. at risk

Pembrolizumab+Platinum+PEM	65	47	26	12	6	3
Pembrolizumab+CBDCA+PTX/nab-PTX	23	13	7	5	3	1
Atezolizumab+CBDCA+nab-PTX	8	6	2	0	0	0
Atezolizumab+CBDCA+PTX+BEV	29	15	6	3	3	1

**B**

No. at risk

Pembrolizumab+Platinum+PEM	65	59	40	28	19	5
Pembrolizumab+CBDCA+PTX/nab-PTX	23	21	18	12	6	3
Atezolizumab+CBDCA+nab-PTX	8	8	3	0	0	0
Atezolizumab+CBDCA+PTX+BEV	29	25	18	12	8	3